Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye
Robert Sambursky Coastal Eye Institute, Cornea and Comprehensive Ophthalmology, Bradenton, FL, USA Background: The presence of clinically significant inflammation has been confirmed in the tears of 40%–65% of patients with symptoms of dry eye. Ocular surface inflammation may lead to tear...
Enregistré dans:
Auteur principal: | Sambursky R |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2016
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/0d92b21ed1354c6897bfaf3bd18e2ab4 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
par: Deveney T, et autres
Publié: (2018) -
Short-Term Therapeutic Effects of Topical Corticosteroids on Refractory Dry Eye Disease: Clinical Usefulness of Matrix Metalloproteinase 9 Testing as a Response Prediction Marker
par: Ryu KJ, et autres
Publié: (2021) -
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
par: Tauber J, et autres
Publié: (2018) -
Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
par: Matossian C, et autres
Publié: (2021) -
Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
par: Rhee MK, et autres
Publié: (2017)